#18: Brincidofovir for the Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid-organ Transplant Recipients
Londeree J, Garro R, Romero R, George R, Winterberg P, Liverman R, Serluco A, Shin S, Yildirim I. #18: Brincidofovir for the Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid-organ Transplant Recipients. Journal Of The Pediatric Infectious Diseases Society 2021, 10: s3-s3. DOI: 10.1093/jpids/piaa170.008.Peer-Reviewed Original ResearchPediatric SOT patientsAcute kidney injuryHAdV infectionSolid organ transplantationSOT patientsSevere diseaseResolution of AKIPediatric solid organ transplant recipientsSolid organ transplant recipientsAntiviral treatment optionsInvestigational antiviral drugsPediatric transplant centersBaseline clinical characteristicsDays of therapyMainstay of treatmentResolution of symptomsSubset of patientsHuman adenovirus infectionHAdV viral loadsAdenovirus viremiaBaseline creatinineGraft involvementGraft lossHAdV viremiaReduced immunosuppression#77: Impact of Targeted Tacrolimus Levels on BK Polyomavirus DNAemia Among Pediatric Kidney Transplant Recipients
Yildirim I, Liverman R, Serluco S, George R, Garro R, Winterberg P. #77: Impact of Targeted Tacrolimus Levels on BK Polyomavirus DNAemia Among Pediatric Kidney Transplant Recipients. Journal Of The Pediatric Infectious Diseases Society 2021, 10: s4-s4. DOI: 10.1093/jpids/piaa170.011.Peer-Reviewed Original ResearchPost-intervention cohortKidney transplant recipientsTacrolimus levelsTransplant recipientsKidney transplantPediatric kidney transplant recipientsPre-intervention cohortTacrolimus target levelsQuality improvement studyAllograft dysfunctionBK viremiaGraft lossImmunosuppression reductionUncontrolled viremiaBK nephropathyInfectious complicationsKidney transplantationMedian ageSerious complicationsMedian timeBK polyomavirusIncidence rateDNAemiaTrough targetsProspective monitoring